Skip to content

Ketamine: all studies

Page 119 of 449: studies 1,181 to 1,190 of 4,483, newest first. Back to the ketamine overview

Research

Ketamine, Esketamine, and Arketamine: Their Mechanisms of Action and Applications in the Treatment of Depression and Alleviation of Depressive Symptoms.

Biomedicines October 9, 2024 Piotr Kawczak, Igor Feszak, Tomasz Bączek 50 citations

Research over the past years has compared the enantiomers (S)-ketamine (esketamine) and (R)-ketamine (arketamine) of the previously known racemic mixture called ketamine (R/S-ketamine). Esketamine has been found to be more potent, offering three times stronger analgesic effects and 1.5 times greater anesthetic efficacy than arketamine. It provides smoother anesthesia with fewer side effects and...

Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome.

npj Mental Health Research October 6, 2024 Jack D. C. Dahan, David Dadiomov, Tijmen Bostoen et al. 13 citations

There is some evidence that the subjective effects of ketamine and other psychedelics like psilocybin are crucial for their therapeutic outcomes, such as treatment of depression or substance use disorder (SUD). We performed a meta-analysis and systematic review on the correlation of subjective symptoms and dissociation versus ketamine-induced therapeutic outcomes in patients with depression or...

DOI: 10.1038/s44184-024-00091-w (opens in new tab) Full text (opens in new tab) Psychedelic therapy Therapeutic efficacy Mental health treatment Ketamine research +1

Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting.

The Journal of Clinical Psychiatry October 2, 2024 Mia C Santucci, Mina Ansari, Sina Nikayin et al. 12 citations

Background: Bipolar disorder represents a significant source of morbidity and elevated mortality risk. Ketamine has emerged as a powerful antidepressant; however, there have been few trials of ketamine in bipolar depression and no trials with esketamine in bipolar depression, and few data exist from real-world settings. Here, we report outcomes from a cohort of patients with bipolar depression...

DOI: 10.4088/JCP.24m15376 (opens in new tab) Full text (opens in new tab) Ketamine therapy Bipolar disorder Depression treatment Clinical trials +1

Ketamine and Esketamine Use for Mood Disorders with Psychosis: A Systematic Review of Dissociative and Psychotic Symptoms

CNS Spectrums October 1, 2024 Renzo Costa, Ayyub Imtiaz, Jacob Adelman et al.

Introduction Ketamine is used off-label for suicidality and mood disorders, whereas esketamine is FDA-approved for treatment-resistant depression in adults. However, many of these studies have excluded patients with a history of or currently presenting with psychosis. A significant number of patients who have primary mood disorders with psychotic features need novel psychopharmacological...

Differential effects of repeated fluoxetine and ketamine administration on behavioral and pharmacological stressor-induced depression of digging behavior in mice.

Experimental and Clinical Psychopharmacology October 1, 2024 Kaitlyn J Partridge, Todd M. Hillhouse 1 citation

Major depressive disorder is a multifactorial disorder that originates from a complex web of variables and overlaps with similar disorders (e.g., depression and anxiety). As such, animal models should account for the considerable symptom overlap between psychiatric disorders. We sought to extend the findings of behavioral assays that encompass both anxiety and stress/depression components. To...

DOI: 10.1037/pha0000711 (opens in new tab) Full text (opens in new tab) Antidepressants Stress response Personalized medicine Psychiatric treatment +1

Drug dependence and prescribing ketamine for treatment-resistant depression in Australia and New Zealand.

Australian & New Zealand Journal of Psychiatry October 1, 2024 Alistair Carroll, Adam Bayes, Mark Montebello et al. 10 citations

Ketamine is a restricted and regulated medication in Australia and New Zealand, which has implications when considering treatment for patients with treatment-resistant depression and a history of illicit drug use, abuse or dependence. Regulations governing prescription of ketamine for treatment-resistant depression vary between jurisdictions in Australia and New Zealand, though most restrict...

DOI: 10.1177/00048674241242315 (opens in new tab) Full text (opens in new tab) Drug dependence Regulations Ketamine therapy Mental health treatment +3

Comparison of Nebulized Ketamine to Intravenous Subdissociative Dose Ketamine for Treating Acute Painful Conditions in the Emergency Department: A Prospective, Randomized, Double-Blind, Double-Dummy Controlled Trial.

Annals of emergency medicine October 1, 2024 Tommy Nguyen, Mo Mai, Amulya Choudhary et al. 11 citations

We aimed to assess and compare the analgesic efficacy and adverse effects of intravenous subdissociative-dose ketamine to nebulized ketamine in emergency department (ED) patients with acute painful conditions. We conducted a prospective, randomized, double-blind, double-dummy clinical trial in adult patients (ages 18 and older) with a numerical rating scale pain score of ≥5. We randomized...

DOI: 10.1016/j.annemergmed.2024.03.024 (opens in new tab) Full text (opens in new tab) Pain management Ketamine therapy Emergency medicine Medical research +1

Ketamine subcutaneous continuous infusion for depressive symptoms at home: A case report beyond pain use.

Palliative & Supportive Care October 1, 2024 Carolina Simões, Miguel Julião, Patrícia Calaveiras et al. 1 citation

Ketamine has been widely used in refractory pain as an opioid adjuvant. Evidence suggests that ketamine can also have an essential role in easing depressive symptoms. Its rapid onset of action makes it a valuable choice in palliative care. We present a case of a 70-year-old man with stage IV renal carcinoma and bone metastasis. The main symptoms included neuropathic pain, depression, and a...

DOI: 10.1017/S1478951524000798 (opens in new tab) Full text (opens in new tab) Depressive symptoms Home-based palliative care Subcutaneous continuous infusion Ketamine therapy +3

Out-of-Hospital Intranasal Ketamine as an Adjunct to Fentanyl for the Treatment of Acute Traumatic Pain: A Randomized Clinical Trial.

Annals of emergency medicine October 1, 2024 Jason T McMullan, Christopher A Droege, Kathleen M Chard et al. 5 citations

To evaluate if out-of-hospital administration of fentanyl and intranasal ketamine, compared to fentanyl alone, improves early pain control after injury. We conducted an out-of-hospital randomized, placebo-controlled, blinded, parallel group clinical trial from October 2017 to December 2021. Participants were male, aged 18 to 65 years, receiving fentanyl to treat acute traumatic pain prior to...

Differential effects of opioid receptor antagonism on the anti-dyskinetic and anti-parkinsonian effects of sub-anesthetic ketamine treatment in a preclinical model.

Neuropharmacology October 1, 2024 Carolyn J Stopera, Mitchell J Bartlett, Chenxi Liu et al. 9 citations

Sub-anesthetic ketamine treatment has been shown to be an effective therapy for treatment-resistant depression and chronic pain. Our group has previously shown that sub-anesthetic ketamine produces acute anti-parkinsonian, and acute anti-dyskinetic effects in preclinical models of Parkinson's disease (PD). Ketamine is a multifunctional drug and exerts effects through blockade of...

DOI: 10.1016/j.neuropharm.2024.110047 (opens in new tab) Full text (opens in new tab) 6-hydroxydopamine Levodopa-induced dyskinesia Microdialysis Naloxone +6